https://www.selleckchem.com/pr....oducts/ziritaxestat.
As the most popular intrinsic neoplasm throughout the brain, glioblastoma multiforme (GBM) is resistant to existing therapies. Due to its invasive nature, GBM shows a poor prognosis despite aggressive surgery and chemoradiation. Therefore, identifying and understanding the critical molecules of GBM can develop new therapeutic strategies. Glutamatergic signaling dysfunction has been well documented in neurodegenerative diseases as well as GBM. Inhibition of glutamate receptor activation or extracellular glutamate release by specific
Aimer
Commentaire
Partagez
